STVN
Stevanato Group S.p.A.20.89
-0.41-1.92%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Mid-teens GLP growth; capacity tight
Q&A pegged 2026 GLP-1 growth at mid-teens after 50% surge, reflecting normalization post-launch buildup, while stressing ongoing capacity constraints for Nexa syringes and cartridges across high-value lines. Engineering's guide for mid-single to low-double digit decline stems from elongated sales cycles despite doubled site acceptance rates and a robust pipeline in visual inspection. Non-GLP biologics pipeline expands via 40% more premium customers; RTU vials eye mid-high single-digit growth. Latina/Fishers ramps progress but stay dilutive. Fix takes longer than expected.
Key Stats
Market Cap
5.70BP/E (TTM)
34.82Basic EPS (TTM)
0.60Dividend Yield
0%IPO
Employees
Sector
Industry
ATR
AptarGroup, Inc.
122.83+0.50
AVTR
Avantor, Inc.
11.20-0.08
BAX
Baxter International Inc.
19.05-0.48
BDX
Becton, Dickinson and Company
196.39-3.70
NNNN
Anbio Biotechnology
28.01-0.39
SHTPY
-
7.65+0.00
SOAGY
Sartorius AG
56.43-0.16
STE
STERIS plc (Ireland)
253.03-1.04
STSS
Sharps Technology Inc.
2.22+0.00
WST
West Pharmaceutical Services, I
266.44-5.42